130 related articles for article (PubMed ID: 1115842)
1. Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism.
Cade J; Hirsh J; Regoeczi E
Blood; 1975 Apr; 45(4):563-8. PubMed ID: 1115842
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a direct latex-agglutination technic with the tanned red cell hemagglutination inhibition immunoassay (TRCHII) for semiquantitation of fibrinogen/fibrin degradation products.
Wilson JE; Thornton RD
Am J Clin Pathol; 1976 Apr; 65(4):528-32. PubMed ID: 1266814
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of tests of fibrin metabolism in patients predisposed to pulmonary embolism.
Bynum LJ; Crotty CM; Wilson JE
Arch Intern Med; 1979 Mar; 139(3):283-5. PubMed ID: 426574
[TBL] [Abstract][Full Text] [Related]
4. The detection of fibrinogen-fibrin degradation products by means of a new antibody-coated latex particle.
Garvey MB; Black JM
J Clin Pathol; 1972 Aug; 25(8):680-2. PubMed ID: 5076802
[TBL] [Abstract][Full Text] [Related]
5. Serum fibrin-fibrinogen degradation products after experimental pulmonary embolism.
Jones DR; Ruckley CV; Owens R; Cash JD
Br J Surg; 1974 Oct; 61(10):811-3. PubMed ID: 4415741
[No Abstract] [Full Text] [Related]
6. Serum fibrin-fibrinogen degradation products associated with postoperative pulmonary embolus and venous thrombosis.
Ruckley CV; Das PC; Leitch AG; Donaldson AA; Copland WA; Redpath AT; Scott P; Cash JD
Br Med J; 1970 Nov; 4(5732):395-8. PubMed ID: 5481516
[TBL] [Abstract][Full Text] [Related]
7. Resolution of experimental pulmonary emboli with heparin and streptokinase in different dosage regimens.
Hirsh J; Cade JF; Regoeczi E; Gent M; Buchanan MR; Hynes DM
J Clin Invest; 1974 Oct; 54(4):782-91. PubMed ID: 4430712
[TBL] [Abstract][Full Text] [Related]
8. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
9. Tests of fibrin metabolism in recurrent venous thromboembolism.
Bynum LJ; Parkey RW; Wilson JE
Arch Intern Med; 1977 Oct; 137(10):1385-9. PubMed ID: 921420
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of hemagglutination inhibition, staphylococcal clumping, and latex agglutination tests for canine fibrinolytic degradation products.
Chen JP; Williams TK; Legendre AM
Am J Vet Res; 1981 Dec; 42(12):2049-52. PubMed ID: 7340573
[TBL] [Abstract][Full Text] [Related]
11. [Detection of fibrinogen and fibrin degradation products (FDP) and its clinical significance].
Fujimaki M; Ikematsu S; Takeuchi I
Nihon Rinsho; 1973 Apr; 31(4):798-804. PubMed ID: 4580396
[No Abstract] [Full Text] [Related]
12. Problems with streptokinase therapy in acute pulmonary embolism.
Schwartz JM; Friedman SA; Schreiber ZA; Tsao LL; Richter IH
Surgery; 1973 Nov; 74(5):727-33. PubMed ID: 4742757
[No Abstract] [Full Text] [Related]
13. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
[TBL] [Abstract][Full Text] [Related]
14. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems.
Hunt FA; Rylatt DB; Hart RA; Bundesen PG
Br J Haematol; 1985 Aug; 60(4):715-22. PubMed ID: 3896298
[TBL] [Abstract][Full Text] [Related]
15. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products.
Connaghan DG; Francis CW; Ryan DH; Marder VJ
Am J Clin Pathol; 1986 Sep; 86(3):304-10. PubMed ID: 3751995
[TBL] [Abstract][Full Text] [Related]
17. Fibrin-fibrinogen degradation products in cerebrospinal fluid of patients admitted to a psychiatric unit.
Hunter R; Thomson T; Reynolds CM; Pitcher PM
J Neurol Neurosurg Psychiatry; 1974 Mar; 37(3):249-51. PubMed ID: 4829529
[TBL] [Abstract][Full Text] [Related]
18. Urinary fibrin-fibrinogen degradation products (FDP) in renal diseases and during thrombolytic therapy.
Hedner U
Scand J Clin Lab Invest; 1973 Oct; 32(2):175-82. PubMed ID: 4588514
[No Abstract] [Full Text] [Related]
19. Indices of fibrinogen proteolysis and platelet activation during the resolution of pulmonary embolism.
Yudelman I
Thromb Haemost; 1987 Feb; 57(1):11-6. PubMed ID: 2954258
[TBL] [Abstract][Full Text] [Related]
20. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
Thromb Haemost; 1996 Sep; 76(3):339-43. PubMed ID: 8883267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
